Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. has shown promising growth potential through the expansion of its Cortrophin sales force, which has significantly contributed to increased success and revenue forecasts related to the product. The sustained positive performance indicated by the weekly TRx tracker suggests that the company is likely to exceed previous revenue expectations for Cortrophin, supporting further estimates for revenue growth. Additionally, ANI's data-driven approach enhances its ability to navigate payer-related inquiries, thereby improving the likelihood of securing approvals for prescriptions and optimizing its market position.

Bears say

The financial outlook for ANI Pharmaceuticals Inc is negatively affected by several key factors including a substantial debt load exceeding $600 million, which raises concerns about the company's financial stability. Additionally, various risks such as pricing pressures on branded and generic drugs, reimbursement uncertainties, and competitive threats further complicate its market position. Moreover, historical reputational risks associated with the ACTH category may also hinder investor confidence moving forward.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.